Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Vanda Pharmaceuticals Inc

Healthcare US VNDA

6.03USD
-0.22(3.52%)

Last update at 2026-06-05T20:17:00Z

Day Range

6.026.29
LowHigh

52 Week Range

3.296.76
LowHigh

Fundamentals

  • Previous Close 6.25
  • Market Cap289.83M
  • Volume713805
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-20.62700M
  • Revenue TTM177.60M
  • Revenue Per Share TTM3.08
  • Gross Profit TTM 230.10M
  • Diluted EPS TTM-0.09

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 11.30M 42.36M 31.66M 29.03M 25.35M
Minority interest - - - - -
Net income 6.28M 33.15M 23.34M 115.55M 25.21M
Selling general administrative 136.49M 124.05M 140.51M 129.74M 105.75M
Selling and marketing expenses - - - - -
Gross profit 230.10M 243.05M 224.80M 202.70M 172.61M
Reconciled depreciation 2.73M 2.84M 2.86M 2.89M 2.96M
Ebit 6.33M 42.16M 27.24M 22.81M 21.74M
Ebitda 7.84M 43.64M 30.10M 24.32M 23.27M
Depreciation and amortization 1.52M 1.48M 2.86M 1.50M 1.53M
Non operating income net other - - - - -
Operating income 6.33M 42.16M 27.24M 22.81M 21.74M
Other operating expenses 248.05M 226.52M 220.93M 204.38M 171.38M
Interest expense -4.97100M 0.20M 4.42M 6.22M 0.00000M
Tax provision 5.03M 9.21M 8.32M -86.52500M 0.14M
Interest income - - - - -
Net interest income - - - - -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 5.03M 9.21M 8.32M -86.52500M 0.14M
Total revenue 254.38M 268.68M 248.17M 227.19M 193.12M
Total operating expenses 223.77M 200.89M 197.56M 179.89M 150.87M
Cost of revenue 24.28M 25.63M 23.36M 24.49M 20.51M
Total other income expense net 4.97M 0.20M 4.42M 6.22M 3.61M
Discontinued operations - - - - -
Net income from continuing ops 6.28M 33.15M 23.34M 115.55M 25.25M
Net income applicable to common shares 6.28M 33.15M 23.34M 115.55M 25.21M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 648.44M 634.25M 593.79M 533.46M 483.75M
Intangible assets 121.37M 18.57M 20.08M 21.56M 23.04M
Earning assets - - - - -
Other current assets 9.17M 17.73M 12.00M 10.09M 14.50M
Total liab 103.53M 107.05M 88.86M 80.19M 72.80M
Total stockholder equity 544.91M 527.20M 504.93M 453.27M 410.94M
Deferred long term liab - - - - -
Other current liab 75.75M 76.42M 71.18M 63.82M 57.36M
Common stock 0.06M 0.06M 0.06M 0.06M 0.05M
Capital stock 0.06M 0.06M 0.06M 0.06M 0.05M
Retained earnings -155.39200M -157.90100M -164.17600M -197.32800M -220.66500M
Other liab - 6.80M 4.39M 2.76M 0.84M
Good will - - - - -
Other assets - 85.42M 83.03M 88.16M 91.53M
Cash 135.82M 135.03M 52.07M 61.03M 45.07M
Cash and equivalents - - - - -
Total current liabilities 87.70M 91.44M 74.42M 65.94M 59.51M
Current deferred revenue - - - - -
Net debt -126.41700M -123.88800M -42.01600M -47.41700M -32.61700M
Short term debt 2.40M 2.33M 2.31M 2.12M 2.15M
Short long term debt - - - - -
Short long term debt total 9.40M 11.14M 10.05M 13.61M 12.46M
Other stockholder equity 700.27M 686.24M 669.22M 650.30M 631.31M
Property plant equipment - 2.57M 12.38M 4.14M 3.86M
Total current assets 432.95M 519.29M 478.30M 409.14M 354.14M
Long term investments - - - - -
Net tangible assets - 508.63M 484.85M 431.71M 387.91M
Short term investments 252.44M 331.83M 380.74M 306.71M 267.06M
Net receivables 34.16M 33.51M 32.47M 30.04M 26.37M
Long term debt - - - - -
Inventory 1.36M 1.19M 1.02M 1.28M 1.14M
Accounts payable 9.55M 12.69M 0.93M 31.51M 27.59M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.03000M -1.19300M -0.17500M 0.24M 0.25M
Additional paid in capital - - - - -
Common stock total equity - 0.06M 0.06M 0.06M 0.05M
Preferred stock total equity - - - - -
Retained earnings total equity - -157.90100M -164.17600M -197.32800M -220.66500M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 9.52M 11.38M 8.15M 6.64M 3.85M
Deferred long term asset charges - - - - -
Non current assets total 215.49M 114.95M 115.49M 124.31M 129.61M
Capital lease obligations 9.40M 11.14M 12.37M 13.61M 14.60M
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 50.60M -76.14400M -39.70400M -67.29000M -84.29200M
Change to liabilities 11.79M 3.04M 3.76M 3.51M -0.61800M
Total cashflows from investing activities 49.92M -76.69600M -41.49900M -68.30900M -109.66000M
Net borrowings - - - - -
Total cash from financing activities 0.73M 3.55M 5.63M 6.26M 107.13M
Change to operating activities -0.15100M 4.40M 7.20M -2.00300M 3.96M
Net income 6.28M 33.15M 23.34M 115.55M 25.21M
Change in cash 82.91M -9.02300M 15.96M -16.09900M 27.41M
Begin period cash flow 52.59M 61.61M 45.65M 61.75M 34.34M
End period cash flow 135.50M 52.59M 61.61M 45.65M 61.75M
Total cash from operating activities 31.98M 64.21M 51.77M 45.95M 29.99M
Issuance of capital stock - - 0.00000M 0.00000M 100.87M
Depreciation 2.73M 2.84M 2.86M 2.89M 2.96M
Other cashflows from investing activities - - - -67.29000M -25.00000M
Dividends paid - - - - -
Change to inventory -4.47900M -2.23300M -2.87600M -0.72200M 0.07M
Change to account receivables -1.08900M -2.46900M -3.76700M 2.34M -11.20700M
Sale purchase of stock 0.73M 3.55M 5.63M 6.26M 107.13M
Other cashflows from financing activities 49.92M 3.55M 5.63M 6.26M 6.26M
Change to netincome 19.86M 23.85M 21.31M -72.52400M 11.83M
Capital expenditures 0.68M 0.55M 1.79M 1.02M 25.37M
Change receivables -1.08900M -2.46900M -3.76700M 2.34M -11.20700M
Cash flows other operating -0.15100M 4.39M 6.97M -2.00300M 3.96M
Exchange rate changes - - - - -
Cash and cash equivalents changes 82.64M -8.93200M 15.91M -16.09800M 27.45M
Change in working capital 6.07M 2.74M 4.32M 3.12M -7.79000M
Stock based compensation 16.28M 15.37M 13.36M 13.46M 11.67M
Other non cash items -0.50700M 3.37M 1.71M -1.31400M 0.17M
Free cash flow 31.30M 63.66M 49.98M 44.93M 4.62M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
VNDA
Vanda Pharmaceuticals Inc		 -0.22 3.52% 6.03 - 30.30 1.23 0.44 0.59 12.91
NVO
Novo Nordisk A/S		 -0.79 1.81% 42.96 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.6937 1.57% 43.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 5.09 1.15% 446.83 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 6.72 1.07% 635.45 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

Vanda Pharmaceuticals Inc

2200 Pennsylvania Avenue NW, Washington, DC, United States, 20037

Key Executives

Name Title Year Born
Dr. Mihael H. Polymeropoulos M.D. Founder, Pres, CEO & Chairman of The Board 1960
Mr. Kevin Patrick Moran Sr. VP, CFO & Treasurer 1984
Mr. Timothy Williams Sr. VP, Gen. Counsel & Sec. 1976
Mr. Joakim Wijkstrom Sr. VP & Chief Marketing Officer 1966
Mr. Gunther Birznieks Sr. VP of Bus. Devel. 1970
Mr. Scott L. Howell Chief People Officer NA
Ms. Elizabeth Van Every Head of Corp. Affairs NA
Dr. Mihael H. Polymeropoulos M.D. Founder, President, CEO & Chairman of The Board 1960
Mr. Kevin Patrick Moran Senior VP, CFO & Treasurer 1985
Mr. Timothy Williams Senior VP, General Counsel & Secretary 1976

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions